BIS (thio-hydrazide amide) salts for treatment of cancers

US7579503B2 · kind B2 · utility

Assignee

• Synta Pharmaceuticals Corp. · US

Inventors

• Keizo Koya · Sharon, US
• Lijun Sun · Harvard, US
• Elena Kostik · Arlington, US
• Farid Vaghefi · Santa Clarita, US
• Shoujun Chen · Bedford, US
• Noriaki Tatsuta · Lexington, US
• Guiqing Liang · Concord, US
• Takayo Inoue · Tokyo, JP
• Zhi-Qiang Xia · Acton, US

Key dates

• Filing date: Apr 18, 2008
• Grant date: Aug 25, 2009
• Expiry date: Apr 18, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I):Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation.Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.